Dexamethasone injection Rx
Generic Name and Formulations:
Dexamethasone phosphate (as sodium); 4mg/mL, 10mg/mL; for IV inj; contains sulfites.
Various generic manufacturers
Indications for Dexamethasone injection:
Steroid-responsive disorders when oral therapy not feasible.
Adults and Children:
See literature. Initially usually 0.5–9mg daily IV.
Systemic fungal infection. Live vaccination. Ocular herpes simplex. Cerebral malaria.
Asthma (inj). Strongyloides infestation. Varicella. Vaccinia. Recent MI. Tuberculosis. Latent amebiasis. Hypothyroidism. Cirrhosis. If exposed to chickenpox or measles, consider prophylactic passive immune therapy. Renal insufficiency. Ulcerative colitis. Intestinal anastomoses. Diverticulitis. Peptic ulcer. CHF. Hypertension. Osteoporosis. Diabetes. Myasthenia gravis. Hypoprothrombinemia. Supplement with additional steroids in physiologic stress. Avoid abrupt cessation. Monitor weight, growth, fluid and electrolyte balance. Pregnancy (Cat.C). Nursing mothers: not recommended.
Potentiated by CYP3A4 inhibitors (eg, ketoconazole, macrolides), cyclosporine, estrogens. Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin), ephedrine. May potentiate cyclosporine. May antagonize anticoagulants (monitor), isoniazid, other CYP3A4 substrates (eg, indinavir, erythromycin). Increased risk of arrhythmias with digitalis. May need to adjust dose of antidiabetic agents. Increased GI effects with aspirin. Monitor for hypokalemia with potassium-depleting drugs (eg, amphotericin B, diuretics). Toxic epidermal necrolysis possible with thalidomide. Concomitant indomethacin: may get false-negative on dexamethasone suppression test. May suppress reactions to skin tests.
HPA axis suppression, masks infection, increased susceptibility to infection, glaucoma, cataracts, secondary infections, hypokalemia, hypocalcemia, hypernatremia, hypertension, psychic disorders, myopathy, osteoporosis, peptic ulcer, dermal atrophy, increased intracranial pressure, carbohydrate intolerance, inj site reactions.
Formerly known under the brand names Decadron, Hexadrol.
Clinical Pain Advisor Articles
- Risks Associated With Co-Administration of Aspirin and Other NSAIDs
- Stages of Low Back Pain Have Specific Sets of Clinical Indicators
- FDA Approves Aimovig for Migraine Prevention
- First Non-Opioid Drug Approved for Managing Opioid Withdrawal Symptoms
- Pain Interference Associated With Depression, Pain Self-Efficacy in Chronic Musculoskeletal Pain
- Effect of Prescription Drug Monitoring Programs on Fatal, Nonfatal Drug Overdoses
- Standardized SCS Workflow May Effectively Alleviate Failed Back Surgery Syndrome-Related Pain
- Marijuana Legalization and Opioid Prescribing Rates
- Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes
- Interbrain Coupling During Handholding Associated With Analgesia, Empathy
- Opioid-Related Adverse Drug Events Associated With Worse Patient, Cost Outcomes
- Education Plus Exercise, Single Corticosteroid Injection Effective in Long Term for Gluteal Tendinopathy
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Naloxone Training Beneficial for PA Students
- Supervised Injection Sites Hailed as the Latest Strategy to Fight the Opioid Crisis